July 29, 2019Open Access

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Enfortumab vedotin demonstrated a clinically meaningful response rate with a manageable and tolerable safety profile in patients with locally advanced or metastatic urothelial carcinoma who were previously treated with platinum and anti-PD-1/L1 therapies.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Rosenberg et al. (Mon,) studied this question.

synapsesocial.com/papers/69dabf804e9a02dbaa68446c https://doi.org/https://doi.org/10.1200/jco.19.01140

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation2008 · 593 citations
2Mature results from EV-101: A phase I study of enfortumab vedotin in patients with metastatic urothelial cancer (mUC).2019 · 25 citations
3Stimuli-responsive prodrug-based cancer nanomedicine2020 · 179 citations
4Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study2000 · 2,287 citations
5Docetaxel with or without ramucirumab after immune checkpoint inhibition in platinum-refractory metastatic urothelial carcinoma (mUC): Prespecified subgroup analysis from the phase 3 RANGE trial.2018 · 10 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo